HomeCompareCLSD vs PEP

CLSD vs PEP: Dividend Comparison 2026

CLSD yields 487.80% · PEP yields 3.63%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLSD wins by $50753.75M in total portfolio value
10 years
CLSD
CLSD
● Live price
487.80%
Share price
$0.41
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$50753.89M
Annual income
$36,168,404,531.85
Full CLSD calculator →
PEP
PepsiCo Inc.
● Live price
3.63%
Share price
$156.82
Annual div
$5.69
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$141.9K
Annual income
$61,875.67
Full PEP calculator →

Portfolio growth — CLSD vs PEP

📍 CLSD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLSDPEP
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLSD + PEP cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLSD pays
PEP pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSD
Annual income on $10K today (after 15% tax)
$41,463.41/yr
After 10yr DRIP, annual income (after tax)
$30,743,143,852.07/yr
PEP
Annual income on $10K today (after 15% tax)
$308.41/yr
After 10yr DRIP, annual income (after tax)
$52,594.32/yr
At 15% tax rate, CLSD beats the other by $30,743,091,257.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSD + PEP for your $10,000?

CLSD: 50%PEP: 50%
100% PEP50/50100% CLSD
Portfolio after 10yr
$25377.02M
Annual income
$18,084,233,203.77/yr
Blended yield
71.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PEP right now

CLSD
Analyst Ratings
5
Buy
3
Hold
Consensus: Buy
Altman Z
-48.3
Piotroski
2/9
PEP
Analyst Ratings
1
Strong
15
Buy
27
Hold
1
Sell
Consensus: Hold
Price Target
$172.43
+10.0% upside vs current
Range: $156.00 — $191.00
Altman Z
3.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSD buys
0
PEP buys
0
No recent congressional trades found for CLSD or PEP in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLSDPEP
Forward yield487.80%3.63%
Annual dividend / share$2.00$5.69
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$50753.89M$141.9K
Annual income after 10y$36,168,404,531.85$61,875.67
Total dividends collected$49478.61M$123.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: CLSD vs PEP ($10,000, DRIP)

YearCLSD PortfolioCLSD Income/yrPEP PortfolioPEP Income/yrGap
1← crossover$59,480$48,780.49$10,849$509.42+$48.6KCLSD
2$334,811$271,167.03$11,969$750.47+$322.8KCLSD
3$1,784,770$1,426,522.08$13,500$1,124.14+$1.77MCLSD
4$9,016,553$7,106,848.63$15,680$1,721.66+$9.00MCLSD
5$43,202,271$33,554,559.81$18,929$2,715.34+$43.18MCLSD
6$196,483,123$150,256,693.49$24,023$4,450.80+$196.46MCLSD
7$848,895,486$638,658,543.63$32,510$7,669.92+$848.86MCLSD
8$3,487,095,949$2,578,777,778.75$47,709$14,093.60+$3487.05MCLSD
9$13,631,297,985$9,900,105,319.66$77,415$28,083.48+$13631.22MCLSD
10$50,753,893,375$36,168,404,531.85$141,922$61,875.67+$50753.75MCLSD

CLSD vs PEP: Complete Analysis 2026

CLSDStock

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Full CLSD Calculator →

PEPConsumer Staples

PepsiCo, Inc. manufactures, markets, distributes, and sells various beverages and convenient foods worldwide. The company operates through seven segments: Frito-Lay North America; Quaker Foods North America; PepsiCo Beverages North America; Latin America; Europe; Africa, Middle East and South Asia; and Asia Pacific, Australia and New Zealand and China Region. It provides dips, cheese-flavored snacks, and spreads, as well as corn, potato, and tortilla chips; cereals, rice, pasta, mixes and syrups, granola bars, grits, oatmeal, rice cakes, simply granola, and side dishes; beverage concentrates, fountain syrups, and finished goods; ready-to-drink tea, coffee, and juices; dairy products; and sparkling water makers and related products. It serves wholesale and other distributors, foodservice customers, grocery stores, drug stores, convenience stores, discount/dollar stores, mass merchandisers, membership stores, hard discounters, e-commerce retailers and authorized independent bottlers, and others through a network of direct-store-delivery, customer warehouse, and distributor networks, as well as directly to consumers through e-commerce platforms and retailers. The company was founded in 1898 and is headquartered in Purchase, New York.

Full PEP Calculator →
📬

Get this CLSD vs PEP comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSD vs SCHDCLSD vs JEPICLSD vs OCLSD vs KOCLSD vs MAINCLSD vs MOCLSD vs PMCLSD vs GIS

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.